HC Wainwright Estimates Acelyrin’s Q1 Earnings (NASDAQ:SLRN)

Acelyrin, Inc. (NASDAQ:SLRN) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Acelyrin in a research report issued to clients and investors on Tuesday, January 7th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.44) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $6.00 target price on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Acelyrin’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.15) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at ($1.04) EPS.

Several other equities analysts have also commented on the company. Citigroup reduced their price target on Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday. Wells Fargo & Company reduced their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.60.

Acelyrin Price Performance

NASDAQ SLRN opened at $2.06 on Thursday. The business’s 50-day simple moving average is $4.09 and its 200-day simple moving average is $4.83. The firm has a market capitalization of $206.67 million, a P/E ratio of -0.84 and a beta of 1.94. Acelyrin has a 1-year low of $1.91 and a 1-year high of $8.89.

Institutional Investors Weigh In On Acelyrin

Institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. bought a new position in Acelyrin during the 2nd quarter worth $49,000. HighTower Advisors LLC bought a new position in Acelyrin during the 3rd quarter worth $50,000. Virtu Financial LLC bought a new position in Acelyrin during the 3rd quarter worth $50,000. Intech Investment Management LLC bought a new position in Acelyrin during the 3rd quarter worth $77,000. Finally, US Bancorp DE grew its stake in Acelyrin by 77.1% during the 3rd quarter. US Bancorp DE now owns 16,854 shares of the company’s stock worth $83,000 after buying an additional 7,336 shares during the last quarter. 87.31% of the stock is currently owned by institutional investors.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.